It is thought that the secondary pathway by which AOD9604 causes fat loss, the pathway that is independent of beta-3-adrenergic receptor activation, may play a role in improving metabolic metrics even while it boosts fat loss- AOD9604 exhibits minimal side effects, high oral and excellent subcutaneous bioavailability in mice
Fair skin, immunosuppression, history of intense UV exposure
[DOI] [PubMed] [Google Scholar] 6.Marx N., Federici M., Schtt K., et al
There have been postmarketing reports of serious hypersensitivity reactions, including anaphylactic reactions and angioedema, in patients treated with SOLIQUA 100/33 [see Adverse Reactions (6.1)]
Never deviate from the trial protocol without consulting the research team